STEROIDS IN THE TREATMENT OF CHRONIC DISEASES by SHARMA P et al.
Vol 12, Issue 7, 2019
Online - 2455-3891 
Print - 0974-2441
STEROIDS IN THE TREATMENT OF CHRONIC DISEASES
SHARMA P, IMAM S, MEHTA DK*
Department of Pharmaceutical Chemistry, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Ambala, 
Haryana, India. Email: dkmehta17@rediffmail.com
Received: 11 April 2019, Revised and Accepted: 24 May 2019
ABSTRACT
Since their identification, which was almost 80 years ago, steroids have played a prominent role in the treatment of many disease states such as 
chronic obstructive pulmonary disease, asthma, rheumatoid arthritis, and inflammatory bowel disease. Many of the clinical roles of steroids are 
related to their potent anti-inflammatory and immune-modulating properties. Numerous skin diseases are successfully treated with systemic 
steroids. Corticosteroids, though they are lifesaving drugs, produce adverse reactions which may be mild or life threatening. Steroids have diverse 
effects on various systems of the body. Therefore, educational interventions among physician, patients, as well as students should be carried out to 
further enhance rational drug use. The purpose of this review was to identify the most commonly prescribed steroids and their side effects, basic 
pharmacology, complications, as well as the assessment of patient knowledge about the use of steroids in tertiary care teaching hospitals.
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INTRODUCTION
Steroids such as corticosteroids as well as androgenic steroids have a 
wide range of application in immunological, pulmonary, oncological, 
inflammatory, and dermatological diseases. Traditional teaching 
suggests that corticosteroids should be avoided during acute infectious 
episodes for fear of compromising the immune response [1].
The term steroid is relevant to a wide range of molecules showing 
varying physiological effects [2]. In respiratory, corticosteroids are 
used to treat acute exacerbations of chronic obstructive pulmonary 
disease (COPD) as well as uncontrolled asthma. They are also used in 
the treatment of hypersensitivity pneumonitis and immune-mediated 
vasculitis [3]. Anabolic steroids are used by athletes and bodybuilders 
to enhance their performance. Anabolic steroids history can be traced 
before the term steroid was even used as early as the 1930s. A synthetic 
form of testosterone (a male hormone) created by a team of scientist 
in the 1930s which helped to treat men who were unable to produce 
enough of the hormones for normal development, growth, and sexual 
functioning [4]. Initially, anabolic steroids were used by bodybuilders, 
but due to its positive effects, it became widely used in other sports also 
such as football, hockey, swimming, volleyball, wrestling, soccer, and 
cycling [5]. The misuse of anabolic steroids started in 1954 Olympics 
by professional athletes when Russian weightlifters were given 
testosterone [6].
Corticosteroids and their biologically active synthetic derivatives 
differ in their metabolic (glucocorticoid) and electrolyte-regulating 
(mineralocorticoid) activities.
Since their discovery in the 1940s, corticosteroids have become 
one of the most widely used and effective treatments for various 
inflammatory and autoimmune disorders. They are used as 
replacement therapy in adrenal insufficiency (at physiologic doses) 
as well as in supraphysiologic doses for the management of various 
dermatologic, ophthalmologic, rheumatologic, pulmonary, hematologic, 
and gastrointestinal (GI) disorders. In the field of respirology, systemic 
corticosteroids are used for the treatment of acute exacerbations of 
COPD and severe, uncontrolled asthma, as well as for inflammatory 
parenchymal lung diseases such as hypersensitivity pneumonitis and 
immune-mediated vasculitis [7].
Inappropriate use of corticosteroids may lead to over or under 
treatment [8], worsening of conditions, or eventually therapy failure. 
Patients may refuse to take corticosteroids because they fear their 
unwanted, documented side effects (e.g., hyperglycemia, osteoporosis, 
weight gain, etc.) [9]. According to the American College of Clinical 
Pharmacy, the clinical pharmacist has an important role to play in 
patient education and promotion of patient adherence [10].
Hence, the clinical pharmacist’s intervention has a positive impact in 
identifying and managing chronic diseases among patients.
This review focuses on the classification and functions of steroids and 
risks associated with their supplementation in chronic diseases. The 
purpose of this review was to identify the most commonly prescribed 
steroids in chronic diseases and their side effects, basic pharmacology, 
complications, as well as the assessment of patient knowledge about 
the use of steroids in tertiary care teaching hospitals.
CLASSIFICATION OF STEROIDS
There are two different types of steroids present in the body. The first 
group is corticosteroids and the second group is androgenic/anabolic 
steroid [11].
Adrenal cortex
Three groups of hormones are produced by adrenal cortex. These 
hormones are synthesized from cholesterol in the adrenal glands 
and gonads. Glucocorticoids, mineralocorticoids, and androgens 
(sex hormones) hormones are referred to as corticosteroids 
(adrenocorticoids) [12].
Glucocorticoids





The stimulation of adrenocorticotropic hormone from the anterior 
pituitary secretes glucocorticoids and it is also secreted by stress. 
The main glucocorticoids include cortisol and corticosterone. Cortisol 
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is synthesized from cholesterol in reticularis and zona fasciculata of 
adrenal cortex [12]. Cortisol helps in the regulation of many metabolic 
processes such as synthesis of glucose from amino acids and fatty acids 
and in liver glycogen deposition [13].





•	 Increased	 reabsorption	 of	 sodium	 and	water	 from	 the	 renal	
tubules [12].
Glucocorticoids are more commonly prescribed for their anti-
inflammatory and immunosuppressive properties [11].
Mineralocorticoids
Mineralocorticoids primarily act on the kidney, where they cause 
sodium and water retention and active excretion of potassium and 
protons. The primary mineralocorticoid is aldosterone, but other 
endogenous hormones such as progesterone and deoxycorticosterone 
have mineralocorticoid function. Aldosterone is synthesized exclusively 
in the zona glomerulosa region of the adrenal cortex. The production of 
aldosterone is influenced by sodium level in blood.




Anabolic steroids are man-made or synthetic modification of testosterone 
which is a male sex hormone. These compounds are collectively known 
as anabolic/androgenic steroids. The term “Androgenic” means male 
sex characteristics and “Anabolic” means muscle building. Anabolic 
androgenic steroids (AASs) can be administered in different forms 
such as oral, intramuscular injection, parenteral, and transdermal [14]. 
Anabolic steroids are of two types, i.e., 17 alpha alkyl derivatives 
(e.g., oxandrolone, oxymetholone, and fluoxymesterone) and 17-beta 
ester derivatives (e.g., testosterone cypionate, testosterone enanthate, 
and nandrolone decanoate). Nandrolone phenpropionate was one of 
the first anabolic steroids used by professional athletes as a doping 
agent in 1960 [15-17].
The main function includes:
•	 Endogenous	androgen	is	responsible	for	secondary	sex	characteristics
•	 Growth	and	development	of	male	sex	organs	[18,19].
CORTICOSTEROIDS: SYNTHESIS, SECRETION, AND 
BIOAVAILABILITY
Corticosteroids consist of glucocorticoids and mineralocorticoids which 
are steroid hormones, synthesized, and released by the adrenal gland 
in response to physiological changes and stress [20]. Glucocorticoids, 
when released from the adrenal gland into the blood circulation, access 
target tissues to regulate physiologic processes such as metabolism, 
skeletal growth, cardiovascular function, and reproduction and immune 
function. Glucocorticoids play the physiological and pharmacological 
functions which are mediated by the intracellular glucocorticoid 
receptor (GR). The GR consists of three fundamental domains: An 
N terminal transactivation domain, a central deoxyribonucleic acid 
(DNA)-binding domain, and a C-terminal ligand-binding domain [21]. 
Mineralocorticoids such as aldosterone help in the regulation of sodium 
concentration in the body [22,23].
GLUCOCORTICOIDS: PHYSIOLOGICAL EFFECT
Metabolism
Glucocorticoid such as cortisol helps in the regulation of carbohydrate, 
nucleic acid, lipid, and protein metabolism. The process of 
gluconeogenesis by the liver is stimulated by cortisol which results in 
increased concentration of blood glucose level [24-26]. In the metabolic 
system, cortisol is involved in the reduction of protein stores which 
is stored in all body cells, except for liver. The main reason for this 
is increased catabolism of protein already in the cell and decreased 
protein synthesis [24,25,27].
Anti-inflammatory effects
A large amount of cortisol shows anti-inflammatory effects. It stabilizes 
lysozyme membrane and decreases the release of lysozymes which 
causes inflammation and results in a decrease in capillary permeability 
preventing loss of plasma proteins into tissues [24-26,28].
Bone and calcium metabolism
Glucocorticoids inhibit the function of osteoblast which results in 
osteopenia and osteoporosis which is the characteristic of the excess 
level of glucocorticoids [24,25].
Blood pressure control
Blood	 pressure	 increased	 by	 glucocorticoids	 involves	 a	 variety	 of	
mechanisms which includes action on kidney and vasculature. The 
sensitivity to pressor agents such as angiotensin-2 and catecholamines 
is increased in the vascular smooth muscle, while the endothelial 
dilation mediated by nitric oxide is reduced [24,25,28].
Central nervous system and mood
While observing the patients clinically with glucocorticoid excess 
and deficiency reveals that the brain is an important target for 
glucocorticoids with euphoria, apathy,depression, lethargy, and 
psychosis are being  important manifestations [24,26].
Developmental changes
Plasma cortisol is required in the last trimester of pregnancy in the 
progression of a variety of systems that are important in extrauterine 
life for the survival of the fetus. These systems involve maturation of 
various enzymes in the liver, pulmonary surfactant production [24,25].
Gut
The risk of developing peptic ulcer disease is increased by chronic 
administration of glucocorticoids and in patients with glucocorticoid 
excess, pancreatitis with fat necrosis is observed [24-26].
MECHANISM OF ACTION OF STEROIDS
Corticosteroids after entering into the cell bind to cytosolic receptors 
which are responsible for transportation of steroids into the nucleus. 
The steroid receptor complex binds to glucocorticoid response elements 
or mineralocorticoid-specific elements and alters gene expression [29].
Glucocorticoids
Glucocorticoid hormones show anti-inflammatory and 
immunosuppressive effects. Its mechanism involves a decline in 
antibody production and a decrease in white blood cells count such as 
a number of lymphocytes, basophils, and eosinophils which ultimately 
decrease the number of T-lymphocytes. This results in the gradual 
destruction of lymphoid tissue which leads to inhibition of normal 
immune response. The Primary effect of glucocorticoids are mentioned 
in (Table 1). The major immunosuppressive effect of glucocorticoids 
appears to be the modulation of the production of cytokines through 
Table 1: Primary effect of glucocorticoids [31]
Anti-inflammatory: Inhibits inflammation by blocking the action of 
inflammatory mediators or by inducing anti-inflammatory mediator
Immunosuppressive: Directly affects T-lymphocytes and suppress 
delayed hypersensitivity reactions
Antiproliferative: Inhibition of DNA synthesis and epidermal cell 
turnover
Vasoconstrictive: Inhibits histamine action and other 
vasoconstrictive mediators DNA deoxyribonucleic acid
DNA: Deoxyribonucleic acid
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inhibition	of	nuclear	factor	B	expression	and	nuclear	translocation.	The	
cytokines are released from immunocompetent cells which mediate 
both the phases of inflammation, i.e., acute and chronic and then 
involve in controlling the immune response. Glucocorticoids also show 
antiallergic properties [30].
Mineralocorticoids
Renin, an enzyme secreted by kidney cells when there occurs a 
reduction in renal blood flow. As a result, the angiotensinogen 
(produced by the liver) is converted into angiotensin which stimulates 
aldosterone production by the adrenal cortex. Aldosterone further 
leads to reabsorption of sodium and water and excretion of potassium 
by the kidneys. This results in increase in blood volume and blood flow 
through the kidneys, suppressing the production of renin and secretion 
of aldosterone [12].
Androgens
Androgens bind to a specific nuclear receptor in a target cell. In muscle 
and liver, testosterone acts as active ligand, but in other tissues, it must 
be metabolized to dihydrotestosterone (DHT) derivatives. Testosterone 
is converted to DHT by enzyme 5-alpha-reductase after diffusing into 
the cells of seminal vesicles, prostate, epididymis, and skin. After that, it 
binds to the receptor. Testosterone is biotransformed to estradiol in the 
brain. The synthesis of specific ribonucleic acids (RNAs) and proteins is 
stimulated by the hormone/receptor complex which binds to DNA [32].
STEROIDS ARE PRESCRIBED IN CHRONIC DISEASES
The commonly prescribed steroids in chronic diseases and their side 
effects are mentioned in (Table 2).
Chronic obstructive pulmonary disease
COPD is a multidimensional disease with a variety of intermediate and 
clinical phenotypes [33]. It is estimated that COPD will become the 
third most common cause of death worldwide by 2030 [34-36]. The 
Global	 Initiative	 for	 Chronic	 Obstructive	 Lung	 Disease	 defined	 COPD	
as “a common preventable and treatable disease characterized by 
persistent airflow limitation that is usually progressive and associated 
with an enhanced chronic inflammatory response in the airway and 
the	lung	to	noxious	particles	or	gases.	Exacerbations	and	comorbidities	
contribute to the overall severity in individual patient” [37]. The 
pulmonary injury involves three stages, i.e., initiation (due to exposure 
to cigarette smoking, pollutants, and infectious agents), progression, 
and consolidation [33]. Symptoms including breathlessness decreased 
the	 quality	 of	 life	 (QOL)	 and	 loss	 of	 lung	 function	 become	 worst	
with acute exacerbations of COPD [38,39]. COPD is associated with 
chronic	 bronchitis	 and	 emphysema.	 The	 British	 Medical	 Research	
Council defined chronic bronchitis as “daily productive cough for at 
least 3 consecutive months for more than 2 successive years” [40]. 
The treatment of COPD includes smoking cessation and pulmonary 
rehabilitation.	Besides,	this	other	treatment	consists	of	bronchodilators	
in the early stage and oxygen in the late stage. Short courses of systemic 
corticosteroids often along with antibiotics have been used since 
decades to treat inflammation and exacerbations. However, their side 
effects made them unsuitable to treat long-term stable COPD. In the 
early 1980s, inhaled corticosteroids were given to the patient diagnosed 
with	asthma	as	well	as	COPD	in	combination	with	long-acting	β-agonist.	
The inhaled form of corticosteroids proved to be highly effective in the 
treatment of COPD and asthma [41].
Asthma
Asthma is a respiratory condition which consists of increased airway 
hyperresponsiveness and increased episodes of obstruction and 
inflammation of airway and tissue remodeling [42]. It is observed that 
the prevalence of asthma has been increased rapidly over the past 
few decades and it is estimated that there are 334 million sufferers of 
asthma worldwide. The disease is expected to develop over the next 
15–20 years [43,44]. Asthma is characterized by recurrent episodes of 
cough, wheezing, and breathlessness which can be resolved after using 
bronchodilator medication [45]. Corticosteroid was first used in 1956 
to treat acute asthma exacerbation. Corticosteroids such as prednisone 
that have less mineralocorticoid activity and dexamethasone that 
have no mineralocorticoid activity became more attractive therapies 
to treat asthma. In 1972, Clark discovered the effect of inhaled 
beclomethasone in the treatment of asthma with fewer side effects than 
systemic steroids [46]. Inhaled corticosteroids are the most commonly 
used treatment for asthma which can suppress the characteristic 
inflammation in airways [47].
Table 2: Commonly prescribed steroids in chronic diseases
Generic name Trade name Dosage Side effects, risks
COPD
Prednisolone [58] Orapred, Pediapred 30–40 mg Acne, weight gain, increased appetite, menstrual period 
changes, mood changes
Prednisone [59] Deltasone 30–40 mg Loss	of	appetite,	increased	sweating,	weakness,	
abdominal pain
Budesonide Pulmicort 400–1000 µg/day Pneumonia, cataract, diabetes, glaucoma
Salbutamol Proventil, Ventolin Neb – 2.5–5 mg [60,61] Shaking of arms and feet, irregular heartbeat, sleep 
disturbance, skin rash, and spotting
Ipratropium bromide Atrovent Neb – 0.5 mg [60,61] Flu-like symptoms, nervousness, dry mouth, headache
Terbutaline Terbulin Neb – 5–10 mg Tremor, nervousness, palpitation, dizziness, headache
Asthma
Salbutamol [62] Proventil, Ventolin Neb – 2.5 mg Shaking of arms and feet, irregular heartbeat, sleep 
disturbance, skin rash, and spotting
Methyl prednisolone Medrol 80 mg/day Upset stomach, vomiting, depression
Hydrocortisone Enzone 400 mg/day Redness, swelling, bruising, joint pain, itching
RA
Prednisone Deltasone, Sterapred 5–10 mg Weight gain, increased blood sugar, high blood pressure
Methyl prednisolone Depo-Medrol, Medrol 40–80 mg per ml [54,63] High prevalence of fractures, adrenal insufficiency, 
lowered bone mineral density
Prednisolone Orapred, Pediapred 2.5–15 mg Increased susceptibility of infection, cataract formation, 
cutaneous atrophy, increased risk of fracture [64,65]
Breast	cancer
NPP [66] Durabolin 25–50 mg/ml Acne, increased hair growth, voice changes [67]
Nandrolone decanoate Deca-Durabolin 25–50 mg Acne, increased hair growth, voice changes, increased 
sexual desire
COPD: Chronic obstructive pulmonary disease, RA: Rheumatoid arthritis, NPP: Nandrolone phenylpropionate
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Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease which affects 
nearly 1% population all over the world [48]. It is characterized by 
inflammation of synovial and destruction of a joint which can cause 
severe disability if left untreated [49]. It mainly affects the small joints 
of hands and feet. It is a chronic inflammatory disease which causes 
pain, swelling, and stiffness. The disease has no cure yet. Symptomatic 
treatment can be given to the patients suffering from RA which 
can	 increase	 the	 QOL.	 Treatment	 includes	 disease-modifying	 anti-
rheumatic drugs, nonsteroidal anti-inflammatory drugs, and low-dose 
steroids [50-52]. Glucocorticoids have the ability to reduce signs and 
symptoms in inflammatory disorders; therefore, they are widely used 
to treat RA [53]. Prednisone is an important drug which is used to treat 
different kinds of inflammatory conditions including RA [54].
Breast cancer
Breast	cancer	is	the	type	of	cancer	that	originates	from	breast	tissues,	
mostly from the inner lining of milk ducts or the lobules that supply 
the	ducts	with	milk.	Breast	cancer	 is	 life	 threatening	and	found	to	be	
the most common cause of cancer in women. Worldwide, breast cancer 
is the fifth most common cause of cancer death and comprises 10.4% 
of all cancer incidences in women. The possibility of breast cancer is 
100 times more in women than in men. Cancer cells have similar DNA 
and RNA (but not identical) to the cells of the organism from which they 
are originated [55]. AASs are commonly prescribed in the management 
of various pathological conditions including breast cancer, hereditary 
angioedema, renal insufficiency, and endometriosis [56]. The hormonal 
therapy for breast cancer includes tamoxifen, toremifene, and 
fulvestrant [57].
Adverse drug effects of steroid supplementation
Long-term effect
These effects include – osteoporosis, fractures, osteonecrosis, weight 
gain, hyperglycemia, cataract, glaucoma, cardiovascular disease, 
dyslipidemia, myopathy, psychiatric and cognitive disturbance, 
immunosuppression, and growth and adrenal suppression also 
observed in children, increased risk of infections, decrease in bone 
density, ulcers/GI bleeding, thin skin, bruise easily, and slower healing 
of wounds [68,69].
Short-term effect
These effects includes – skin rash, swelling, hot flush, abdominal 
discomfort, upper respiratory tract infections, spinal conditions, 
allergies, acne, sepsis, venous thromboembolism, insomnia and sleep 
disturbances, gastric irritation, sodium and fluid retention, increased 
appetite and weight gain, and mood changes – agitation and emotional 
lability [70,71].
COMMON SIDE EFFECTS OF STEROIDS
Steroids induced osteoporosis
The most common side effect with long-term use of glucocorticoid is bone 
loss [72]. However, the most significant effect of glucocorticoids in bone 
is an inhibition of bone formation [73-77]. Patient receiving high dose 
of glucocorticoid is at greater risk of developing bone loss as compared 
to patient taking lower dose of the drug. Thus, glucocorticoid-induced 
bone loss is dose dependent [78-81]. The treatment of glucocorticoid-
induced bone loss includes decreasing the dose of glucocorticoid, 
calcium and Vitamin D supplementation, and pharmacologic therapy 
to increase bone density and prevent further bone loss [82]. The dose 
of glucocorticoid and duration of glucocorticoid therapy should be as 
low as possible because even low dose of glucocorticoid therapy can 
decrease bone mineral density [83].
Steroids induced hyperglycemia
Steroids are considered to be the main cause of drug-induced 
hyperglycemia [84]. The mechanism includes their interference with 
signaling cascades in muscle cells, which leads to reduction in insulin-
mediated glucose uptake and synthesis of glycogen [85,86]. Due to 
variations in dose of steroids and the scheme used, the hyperglycemia 
approach should always be individualized [87]. A complete evaluation 
of the degree of glucose intolerance, the patient condition, the degree of 
hyperglycemia, the dose, frequency, and mechanism of corticosteroid 
compound must be made to derive the best therapeutic outcome and 
determine the best treatment approach in each patient [88].
Steroids induced weight gain
Another	side	effect	with	long-term	(≥3	months)	use	of	corticosteroids	
includes weight gain [89] with prolonged use of prednisone 
(1.7–5.8 kg), prednisolone (1.5–4.4 kg), and cortisone (1.5–8.4 kg). 
These drugs are associated with significant weight gain [90-95]. There 
exists considerable variability in the amount of weight gain that patient 
will experience while taking corticosteroids [96]. However, very few 
alternatives are available for corticosteroids. The change in treatment 
regimen can be helpful in decreasing the incidence of weight gain in 
patients. Prednisone can be given in alternate day dosing schedule as it 
can also promote weight loss and reduce weight gain [97].
Gastrointestinal disease
GI side effects include candidiasis, pancreatitis, peptic ulcer disease, 
and GI hemorrhage. Glucocorticoid has shown to increase risk of peptic 
ulceration and GI bleeding, this effect could be due to concomitant 
use of nonsteroidal anti-inflammatory drugs [98-100]. Glucocorticoid 
users have shown another GI complication, i.e., acute pancreatitis [101]. 
However, glucocorticoid use cannot be considered as etiological agent 
in causing acute pancreatitis which is shown by recent study [102].
Cardiovascular disease and dyslipidemia
Glucocorticoid uses are known to cause higher cardiovascular risk, 
including hypertension, hyperglycemia, and obesity. Myopathy 
generally occurs over several weeks to months of glucocorticoid use. 
Proximal muscle weakness and atrophy in both the lower and upper 
extremities are typically present in patients [103,104].
ROLE OF PHARMACIST’S COUNSELING
The management programs of various diseases are usually fulfilled in 
a hospital setting and by physicians. However, community pharmacist 
holds their expertise on various medication and interaction with 
the patients regarding counseling and prescription refill. Therefore, 
they could also contribute their effective role in the management of 
diseases. They could assist asthma and COPD patients to maintain 
their condition and to decrease disease complications. A pharmacist 
could provide suitable information about medications and the 
proper use of inhalers. They could also ask the patients about their 
understanding toward disease and medications, explaining the 
importance of inhaled corticosteroids, provide knowledge to the 
patient regarding potential side effects of inhaled corticosteroids, and 
facilitate medication adherence [105-108]. The effect of pharmacist 
care on asthma patients has been investigated only by a few well-
designed studies [109-114]. Community pharmacies can provide an 
effective	platform	for	cost-effective	treatment	and	health-related	QOL	
in COPD [115-118]. The abuse of topical corticosteroid (TC) has now 
become a global issue [119,120]. Pharmacists are the key to address 
the problem of TC abuse due to a lack of patient awareness of TC 
use, especially in India. This problem arises because, as compared to 
qualified specialist, patients have easy access to the pharmacist in the 
pharmacy [121,122].
DISCUSSION
Corticosteroids, though they are lifesaving drugs, produce adverse 
reactions which may be mild or life threatening. Steroids have 
diverse effects on various systems of the body. Therefore, educational 
interventions among physician, patients, as well as students should be 
carried to further enhance rational drug use. Community pharmacist 
holds their expertise on various medication and interaction with the 
patients regarding counseling and prescription refill. Therefore, they 
could also contribute their effective role in the management of diseases.
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Hence, establishing standard guidelines for prescribers for treating 
any acute and chronic diseases, where steroids necessary is highly 
warranted.
CONCLUSION
Corticosteroids are widely used in the treatment of various autoimmune 
and inflammatory diseases. In this article, we have focused on chronic 
diseases, in which steroids are commonly prescribed. Despite the 
benefits of these agents, their long-term use is highly associated with 
potentially serious adverse effects affecting the GI tract, central nervous 
system, endocrine, musculoskeletal, and cardiovascular system. The 
effects of steroid use can vary widely, and the full spectrum of side 
effects can be present even in patients taking low doses.
Most of the side effects can be minimized through careful patient 
monitoring, instructions regarding the proper use of inhalers, following 
preventive measures including the use of lowest effective dose and 
lower potency agents required to treat various disease conditions.
Strategies regarding lifestyle modification should be advised to the 
patient	to	improve	their	QOL.
The clinical pharmacist’s intervention has a positive impact on 
identifying and managing chronic diseases among patients. Such 
intervention decreases patient’s fear and increases compliance with 
corticosteroid	treatment	plan.	Education	of	the	general	public	through	
media programs and the introduction of continuing medical education 
programs for medical, paramedical personnel, and pharmacists are 
probably the most important steps to be taken to create awareness of 
the hazards of misuse of corticosteroids.
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